Verve Therapeutics Inc 's ROA from the first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Verve Therapeutics Inc 's ROA in the first quarter of 2025?
Verve Therapeutics Inc recorded a cumulative net loss of $-181 million during 12 months ending in the first quarter of 2025, resulting in a negative return on assets (ROA) of -30.45%.

However, within the Healthcare sector 452 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2025 quarter, so far to 3797, from total ROA ranking in the fourth quarter of 2024 at 4433.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter
Y / Y Total Assets Change	-4.83 %	-14.76 %	11.31 %	23.88 %	19.32 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-181	-199	-197	-193	-197
Return On Assets (TTM)	-30.45 %	-33 %	-31.44 %	-31.48 %	-33.8 %
VERV's Total Ranking	# 3797	# 4433	# 3873	# 3888	# 3976
Total Assets (TTM) in million	614	566	581	616	645
Seq. Total Assets Change	8.43 %	-2.53 %	-5.68 %	-4.54 %	-2.88 %
Seq. Net Income Change	-	-	-	-	-

VERV's 5 Years Annual ROA >> Back to VERV Management Effectiveness >> Compare VERV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 179
Sector	# 453
Overall	# 3746

Return On Assets Statistics
High	Average	Low
-27.54 %	-31.05 %	-37.02 %
(Jun 30 2024)		(Dec 31 2021)

Financial Statements
Verve Therapeutics Inc 's Assets	$ 614 million	VERV's Balance sheet
Verve Therapeutics Inc 's Income	$ -31 million	Quarterly VERV's Income Statement
VERV's Income by Division		See VERV's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	FY
Y / Y Total Assets Change	-14.76 %	13.59 %	54.6 %	-	-
Total Assets in million	566	664	585	378	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-199	-200	-157	-120	0
Annual Return On Assets	-35.08 %	-30.11 %	-26.91 %	-31.8 %	-

VERV's 5 Years Annual ROA >> Back to VERV Management Effectiveness >> Compare VERV ROA to its Competitors

More Return On Assets Ratios
VERV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
VERV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for VERV's Competitors
Subscribers only: Roa for Verve Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for VERV's Customers

You may also want to know
VERV's Roi	VERV's Inventory Turnover Ratio	VERV's Growth Rates	VERV's Dividend Comparisons
	VERV's Profitability Ratios	VERV's Asset Turnover Ratio	VERV's Dividend Growth
VERV's Roe	VERV's Valuation Ratios	VERV's Financial Strength Ratios	VERV's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.